We provide evidence that miR-16 directly targets the MAPK pathway at several levels and that its upregulation restores its sensitivity to erlotinib in KRAS-mutated NSCLC both in vitro and in vivo, with results that are better than the TKI–MEK inhibitor combination. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.